AbCellera presents ABCL635 Phase 2 data for menopause symptom treatment
ABCL•AbCellera said week-four Phase 2 data for ABCL635 suggested improved efficacy versus available nonhormonal therapies for moderate-to-severe vasomotor symptoms. It reported more than $790 million in cash and marketable securities and more than $100 million in available government funding.
1. Pipeline and cash update
AbCellera said it completed all 2026 pipeline priorities, advancing three additional programs into its internal pipeline. Its pipeline included two molecules in clinical trials and five programs in IND-enabling activities; cash balances and marketable securities exceeded $790 million, supporting more than three years of pipeline investments.
